P/B
8,5
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
$359.1M
Market Cap • 10/30/2026
1998
(28 years)
Founded
2002
(24 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,2
EPS
—
Market Cap
Market Cap
359,1M
EV
317,8M
EV/Revenue
5,4
EV/EBITDA
-200,3
EV/EBIT
-200,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-13,2%
Total Yield
-13,2%
Payout
0%
Retained Earnings
-227,2M
Profitability
Gross Margin
93,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0,4%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-38,5%
CAGR Net Income 5Y
-27,8%
CAGR EPS 5Y
-28,6%
CAGR OCF 5Y
-34,4%
Leverage
N.D./EBITDA
26
Debt/Equity
0%
Current Ratio
5,8
Quick Ratio
5,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!